Vaginal Toxicity Management in Patients with Locally Advanced Cervical Cancer following Exclusive Chemoradiation-A Nationwide Survey on Knowledge and Attitudes by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gynecology Study Group
- PMID: 36837584
- PMCID: PMC9963963
- DOI: 10.3390/medicina59020385
Vaginal Toxicity Management in Patients with Locally Advanced Cervical Cancer following Exclusive Chemoradiation-A Nationwide Survey on Knowledge and Attitudes by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gynecology Study Group
Abstract
Background and Objective: Exclusive radiotherapy, including external beam radiotherapy (EBRT) and interventional radiotherapy/brachytherapy (IRT/BT), with concurrent cisplatin-based chemotherapy, represents the standard of care in patients with locally advanced cervical cancer (LACC). The emerging topic of vaginal toxicity has become a key endpoint in LACC management, although different approaches and non-standardized procedures were available. Our aim was to analyze a nationwide study of the attitudes of Italian gynecological radiation oncology teams in the management of LACC patients' vaginal toxicities. Methods: A nationwide survey of radiation oncologists specializing in the treatment of gynecological malignancies was performed, using the free SurveyMonkey platform, consisting of 26 items. The questionnaire was proposed by the Italian Association of Radiation Oncologists (AIRO) gynecological working group to all 183 Italian radiation oncology institutions, as per AIRO's website. Results: Fifty-eight questionnaires (31%) were completed and returned. The assessment of acute and late vaginal toxicities was systematic in 32 (55.2%) and 26 (44.8%) centers, respectively. In the case of EBRT, 70.7% of centers, according to the contouring and treatment plan data, did not contour the vagina as an organ at risk (OAR). Vaginal dose constraints were heterogeneous for both EBRT and IRT/BT. Local treatment to prevent vaginal toxicity was prescribed by 60.3% of radiation oncologists, mostly vaginal hyaluronic acid cream, and one center recommended vaginal estrogen preparations. During follow-up visits, vaginal toxicity was considered an issue to be investigated always (n = 31) or in sexually active women only (n = 11). Conclusions: This survey showed that wide variation exists with regard to recording and treating vaginal toxicity after exclusive chemoradiation for cervical cancer, underscoring the need to develop more comprehensive guidelines for contouring e-dose reporting of the vagina, so as to implement clinical approaches for vaginal toxicity.
Keywords: locally advanced cervical cancer; survey; vaginal toxicity.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.Brachytherapy. 2017 Jan-Feb;16(1):126-132. doi: 10.1016/j.brachy.2016.09.009. Epub 2016 Nov 2. Brachytherapy. 2017. PMID: 27816539
-
Prevention and management of radiotherapy-related toxicities in gynecological malignancies. Position paper on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology).Radiol Med. 2024 Sep;129(9):1329-1351. doi: 10.1007/s11547-024-01844-5. Epub 2024 Aug 28. Radiol Med. 2024. PMID: 39198369 Free PMC article.
-
Advances in Radiation Oncology for the Treatment of Cervical Cancer.Curr Oncol. 2022 Feb 9;29(2):928-944. doi: 10.3390/curroncol29020079. Curr Oncol. 2022. PMID: 35200578 Free PMC article. Review.
-
Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review.Int J Gynecol Cancer. 2021 Sep;31(9):1278-1286. doi: 10.1136/ijgc-2020-002310. Epub 2021 Feb 25. Int J Gynecol Cancer. 2021. PMID: 33632703 Review.
-
Concurrent Chemo- Radiobrachytherapy with Cisplatin and Medium Dose Rate Intra- Cavitary Brachytherapy for Locally Advanced Uterine Cervical Cancer.Asian Pac J Cancer Prev. 2018 Oct 26;19(10):2745-2750. doi: 10.22034/APJCP.2018.19.10.2745. Asian Pac J Cancer Prev. 2018. PMID: 30360600 Free PMC article. Clinical Trial.
Cited by
-
Dose escalation with stereotactic body radiotherapy for cervical cancer treatment.BMC Cancer. 2024 Oct 15;24(1):1281. doi: 10.1186/s12885-024-13017-8. BMC Cancer. 2024. PMID: 39407149 Free PMC article.
-
Incidence of vaginal toxicities following definitive chemoradiation in intact cervical cancer: A meta-analysis.J Contemp Brachytherapy. 2024 Jun;16(3):241-256. doi: 10.5114/jcb.2024.141402. Epub 2024 Jun 29. J Contemp Brachytherapy. 2024. PMID: 39629092 Free PMC article. Review.
References
-
- National Comprehensive Cancer Network (NCCN) Guidelines. Cervical Cancer, Version 1.2022. [(accessed on 10 July 2022)]. Available online: http://www.nccn.org.
-
- Cibula D., Pötter R., Planchamp F., Avall-Lundqvist E., Fischerova D., Meder C.H., Köhler C., Landoni F., Lax S., Lindegaard J.C., et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother. Oncol. 2018;127:404–416. doi: 10.1016/j.radonc.2018.03.003. - DOI - PubMed
-
- Mahantshetty U., Poetter R., Beriwal S., Grover S., Lavanya G., Rai B., Petric P., Tanderup K., Carvalho H., Hegazy N., et al. IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer. Radiother. Oncol. 2021;160:273–284. doi: 10.1016/j.radonc.2021.05.010. - DOI - PMC - PubMed
-
- Gay H.A., Barthold H.J., O’Meara E., Bosch W.R., El Naqa I., Al-Lozi R., Rosenthal S.A., Lawton C., Lee W.R., Sandler H., et al. Pelvic Normal Tissue Contouring Guidelines for Radiation Therapy: A Radiation Therapy Oncology Group Consensus Panel Atlas. Int. J. Radiat. Oncol. 2012;83:e353–e362. doi: 10.1016/j.ijrobp.2012.01.023. - DOI - PMC - PubMed